AzTrials
AzTrials

Assisted Reproductive TechniquesNCT03660007

Incidence of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer

An observational study of Assisted Reproductive Techniques and Pregnancy, run by Karolinska Institutet.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In vitro fertilization (IVF) is associated with an increased risk of venous thromboembolism and in particular pulmonary embolism during the first trimester. It is not known whether this increased risk of pulmonary embolism is present both after fresh and frozen embryo transfer. Read more about this study

Who is it for?
Ages 15 to 50 years, women only
What is being tested?
Fresh or frozen embryo transfer IVF
Type of treatment
Surgery or procedure
How many people
902,891 participants
Where
No sites listed yet
Study dates
1 Jan 1992to 31 Dec 2014
How long will I take part?
10 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 50 years
  • Women only
  • No healthy volunteers
  • Child, Adult

Study population: All Swedish women who had given birth at the age of 15-50 years to a first child from the 1st of January 1992 until the 31st of December 2012 .

Who may be able to join

  • Women who had given birth to a first child

Who cannot join

  • Women with previous pregnancies

About this study

Official title: Association of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer: a Population-based Cohort Study

In vitro fertilization (IVF) is associated with an increased risk of venous thromboembolism and in particular pulmonary embolism during the first trimester. It is not known whether this increased risk of pulmonary embolism is present both after fresh and frozen embryo transfer.

Objective: To assess whether the risk of pulmonary embolism and venous thromboembolism during the first trimester of IVF pregnancies is associated with both fresh and frozen embryo transfer.

A population-based cohort study with linked data from nationwide registries on women in Sweden giving birth to their first child 1992-2012

Read the detailed description

A population-based cohort study with data prospectively collected in the nationwide registries in Sweden. Through the national registries the investigators collect data on all women with a child born in Sweden between 1992-2012 and these will be linked to data from the registries by the use of the unique personal identity number.

Study population All women who gave birth at the age of 15-50 years to their first child from the 1st of January 1992 until the 31st of December 2012 comprise the study population. Women will be categorized as either giving birth after IVF or natural conception pregnancies. Data on whether IVF was performed by the use of fresh or frozen embryo transfer will be retrieved.

The registries The national registries in Sweden are considered to have good coverage and validity in general and the Swedish Medical Birth Register (MBR) by the National Board of Health and Welfare in Sweden includes annually 97-99.5 % of all child births in Sweden, up until 2005 all live child births and stillborn from week 28 and thereafter including all child births from week 22. From the MBR and the Swedish national quality registry of assisted reproductive technology, the Q-IVF, the investigators collect information on pre-pregnancy and pregnancy variables. From the Patient registry (PR) ICD codes for PE and overall VTE will be retrieved and from the Swedish register of Education completed years at school and finally from the Swedish Cause of Death Register data on causes of deaths .

Time periods - pregnancy length, the trimesters and postpartum. The follow-up period is from the estimated start of pregnancy until day 42 after delivery, i.e. six weeks postpartum or until an event of PE or other VTE occurred before the end of that period. When determining the trimesters, the best estimation of pregnancy length from the MBR that estimates the days of pregnancy by primary ultrasound will be used or when this is missing by calculation of the first day of the last period. Start of pregnancy is defined as the date of delivery minus the precalculated best estimation of the pregnancy length found in the MBR. Regarding trimesters and postpartum the first trimester is defined to comprise the start of pregnancy, day 0 until day 90, the second trimester from day 91 until day 181 and the third trimester from day 182 until three days before delivery date. Delivery and postpartum period is defined to comprise two days before until six weeks after delivery date, since labor often starts 1-2 days before the actual delivery. Women with pregnancy length exceeding 300 days are to be excluded, considered as extreme values.

Exposures - IVF with fresh or frozen embryo transfer The exposures are either an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation or an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle. These exposures will be compared to a control group of non-exposed women which consists of all pregnant women not listed in the MBR or the IVF-registries and thus considered to be spontaneously conceived, here referred to as natural pregnancy.

Outcome - first incident pulmonary embolism or overall venous thromboembolism The outcome is the occurrence of the first incident PE or first incident VTE during pregnancy or postpartum. All women with pre-pregnancy events are excluded.

The diagnoses of PE and DVT will be defined in the PR with data from 1987 on national inpatient care and from 1997 also outpatient and diagnoses based on the International classification of diseases, ICD. The investigators will use the 8th edition, ICD-8 (1969-1986), for previous diagnoses and exclusions of pre-pregnancy venous thromboembolism and the ninth, ICD-9 (1987-1996), and the tenth edition, ICD-10 (1997--), for both previous and incident diagnoses.

The investigators will use all diagnosis codes for PE (ICD-8: 450.01-03, 450.09, 673.98-99; ICD-9: 415B, 673C; ICD-10: I26.0, I26.9, O882), DVT (ICD-8: 451.00, 451.98-99, 671.01-02, 671.08-09; ICD-9: 451B; ICD-10: I80.1-3, I80.8-9, O22.3, O87.1), portal vein thrombosis (ICD-8 453.09; ICD-9: 452; ICD-10: I81.9), vena cava thrombosis (ICD-8; ICD-9: 453C; ICD-10: I82.2), renal thrombosis (ICD-8; ICD-9: 453D; ICD-10: I82.3), cerebral vein thrombosis (ICD-8: 321.00, 321.09; ICD-9: 325; ICD-10: O22.5, O87.3 and diagnoses codes for other localizations of DVT or emboli (ICD-8: 453.09; ICD-9: 453W, 453X, 671F; ICD-10: I82.8-9, O87.9).

Other predictors or potential confounding factors. The investigators will adjust for potential confounding factors; age, calendar year of delivery, body mass index (BMI), multiple birth, smoking, country of birth and education level. Age is one of the strongest known risk factors for VTE. BMI of 30 or more is a known risk factor for VTE. Another risk factor for VTE is parity, which is one of the reasons why the investigators in this study choose to study only the first child birth in all women in contrast to a previous study where women were included with their first IVF pregnancy. Thus, that study also included women who had given birth to a child before without known IVF with adjustments performed in the statistical analysis for parity.

The continuous variables are to be categorized as follows, age at delivery (<25, 25-29, 30-34, ≥35 years), pre-pregnancy BMI (<25, 25-29 or ≥30 kg/m2), educational level recorded as number of school years (≤9 years -compulsory school, 10-12 years - upper secondary school, >12 years -University level), pre-pregnancy cigarette smoking status (yes/no). Country of birth is either Sweden or other country.

Statistical analyses:

Baseline characteristics of women are to be reported as frequencies and percentages for categorical variables and as median and interquartile range for continuous variables.

Cox regression models are to be used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) in order to assess the association between exposure (IVF with fresh or frozen embryo transfer versus the referent group with natural conception) and each of the two study outcomes. First, HRs are to be estimated under a proportional hazard assumption for the entire pregnancy duration, including the postpartum period. Then, this assumption will be relaxed by allowing the HRs to vary over the different trimesters and the postpartum period by means of a time-dependent Cox regression model. Models are to be adjusted for potential confounders as described above.

Being tested
Fresh or frozen embryo transfer IVF
Keywords
In vitro fertilization, Assisted Reproductive Techniques, Pulmonary embolism, Venous Thromboembolism, Pregnancy
Medical subject headings
Pulmonary Embolism, Venous Thromboembolism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fresh or frozen embryo transfer IVFProcedure or surgery

Study groups in NCT03660007
Study groupRoleWhat they receive
Fresh embryo transferThis exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
Receives: Procedure: Fresh or frozen embryo transfer IVF
Frozen embryo transferThis exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
Receives: Procedure: Fresh or frozen embryo transfer IVF
Natural pregnancySpontaneous pregnancy without IVF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. First incident pulmonary embolism

    Pulmonary embolism during the period from start of pregnancy until pregnancy day 90

    Measured: Estimated start of pregnancy until day 90

Secondary outcomes (1)
  1. First incident venous thromboembolism

    Venous thromboembolism during the period from start of pregnancy until pregnancy day 90

    Measured: Estimated start of pregnancy until day 90

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Sep 2018
  2. Study start1 Jan 1992
  3. Primary completion31 Dec 2012
  4. Study completion31 Dec 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
902,891 participants (actual)
Target duration
10 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT03660007
Sponsor's protocol ID
Fresh or Frozen IVF
Status last verified
Sep 2018
First submitted
30 Aug 2018
Last updated
6 Sep 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Olausson N, Discacciati A, Nyman AI, Lundberg F, Hovatta O, Westerlund E, Wallen HN, Mobarrez F, Bottai M, Ekbom A, Henriksson P. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020 Aug;18(8):1965-1973. doi: 10.1111/jth.14840. Epub 2020 May 11.

    PubMed 32289205

Questions about this trial

What is this clinical trial studying?

An observational study of Assisted Reproductive Techniques and Pregnancy, run by Karolinska Institutet.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First incident pulmonary embolism (time frame: Estimated start of pregnancy until day 90). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03660007, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Sep 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in